My ePortfolio Register   

Abstract | Full HTML Article | PDF ecancer 9 544 /


Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease

Results from two randomised global trials (SOFT & TEXT) designed to newly define the most effective components of adjuvant endocrine therapy for premenopausal women with endocrine responsive disease, showed that for some, those with high risk of relapse, the use of the aromatase inhibitor exemestane together with ovarian function suppression with GnRH analogue (triptorelin) yielded the most favourable treatment outcome compared with tamoxifen. For women with low risk of relapse, treatment with tamoxifen was similar to ovarian function suppression together with either exemestane or tamoxifen. For women with intermediate risk of relapse, ovarian function suppression added to tamoxifen was not inferior to exemestane, while it resulted in superior outcomes compared to tamoxifen alone. Now, these trials provide critical information for the adjuvant treatment of premenopausal women with endocrine responsive breast cancer and are important for the development of future trials for further improvement of adjuvant endocrine therapies for the younger population.

Keywords: Adjuvant endocrine therapy, breast cancer, SOFT & TEXT, ovarian function suppression, exemestane

Loading Article Metrics ... Please wait

Related articles

Case Report: Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma

Abstract | Full Article | PDF | Spanish Published: 05 Mar 2018 /

Case Report: Cauda equina syndrome secondary to leptomeningeal metastases from recurrent primary peritoneal carcinoma

Abstract | Full Article | PDF Published: 26 Feb 2018 /

Case Report: Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus

Abstract | Full Article | PDF Published: 14 Feb 2018 /

Image Report: Radical en bloc peritonectomy in advanced ovarian cancer

Abstract | Full Article | PDF Published: 08 Feb 2018 /

Review: Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development

Abstract | Full Article | PDF Published: 25 Jan 2018 /

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence